VidofludiMus
- Product Name
- VidofludiMus
- CAS No.
- 717824-30-1
- Chemical Name
- VidofludiMus
- Synonyms
- 4SC-101;CS-1196;SC12267);VidofludiMus;VidofludiMus(4SC-101;VIDOFLUDIMUS(4SC-101; SC12267);4SC-101; SC12267;4SC101;4SC 101;2-[(3-Fluoro-3'-methoxy-4-biphenylyl)carbamoyl]-1-cyclopentene-1-carboxylic acid;2-((3-Fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl)carbamoyl)cyclopent-1-enecarboxylic acid;2-((3-Fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl)carbamoyl)cyclopent-1-enecarboxylic acid
- CBNumber
- CB72628520
- Molecular Formula
- C20H18FNO4
- Formula Weight
- 355.36
- MOL File
- 717824-30-1.mol
VidofludiMus Property
- Boiling point:
- 567.5±50.0 °C(Predicted)
- Density
- 1.354±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- insoluble in H2O; insoluble in EtOH; ≥103 mg/mL in DMSO
- form
- solid
- pka
- 4?+-.0.20(Predicted)
- color
- Light yellow to gray
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
- Precautionary statements
-
P280Wear protective gloves/protective clothing/eye protection/face protection.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- 18377
- Product name
- Vidofludimus
- Purity
- ≥98%
- Packaging
- 1mg
- Price
- $37
- Updated
- 2024/03/01
- Product number
- 18377
- Product name
- Vidofludimus
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $116
- Updated
- 2024/03/01
- Product number
- 18377
- Product name
- Vidofludimus
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $213
- Updated
- 2024/03/01
- Product number
- 18377
- Product name
- Vidofludimus
- Purity
- ≥98%
- Packaging
- 25mg
- Price
- $485
- Updated
- 2024/03/01
- Product number
- V305033
- Product name
- Vidofludimus
- Packaging
- 25mg
- Price
- $330
- Updated
- 2021/12/16
VidofludiMus Chemical Properties,Usage,Production
Uses
Vidofludimus is an immunosuppressive drug that inhibits dihydroorotate dehydrogenase (DHODH) and the expression of proinflammatory cytokines including interleukin-17 (IL17A and IL17F) and interferon-gamma.
Biological Activity
vidofludimus (4sc-101, sc12267) is a novel small molecule inhibitor of dihydroorotate dehydrogenase (dhodh) with an ic50 value of 134nmol/l for human dhodh [1].vidofludimus (4sc-101, sc12267) has been reported to dose-dependently inhibit dhodh in an in vitro enzyme assay with ic50 values of 0.134μmol/l, 1.29μmol/l, 10.6μmol/l and 12.9μmol/l in human dhodh, rat dhodh, mouse dhodh and human pbmc, respectively [1]. in addition, vidofludimus has shown the inhibition of proliferation in phytohemagglutinin-induced lymphocytes with an ic50 value of ~13μmol/l. moreover, vidofludimus has been revealed to concentration-dependently inhibit phytohemagglutinin-stimulated interukin-17 secretion from human peripgeral blppd mononuclear cell lines (pbmcs) with an ic50 value of 6 μmol/l [2].
References
[1] kulkarni op1, sayyed sg, kantner c, ryu m, schnurr m, sárdy m, leban j, jankowsky r, ammendola a, doblhofer r, anders hj. 4sc-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in mrl-(fas) lpr mice. am j pathol. 2010 jun;176(6):2840-7.
[2] fitzpatrick lr1, deml l, hofmann c, small js, groeppel m, hamm s, lemstra s, leban j, ammendola a. 4sc-101, a novel immunosuppressive drug, inhibits il-17 and attenuates colitis in two murine models of inflammatory bowel disease. inflamm bowel dis. 2010 oct;16(10):1763-77.
VidofludiMus Preparation Products And Raw materials
Raw materials
Preparation Products
VidofludiMus Suppliers
- Tel
- --
- Fax
- --
- sales@ajchem.in
- Country
- India
- ProdList
- 6100
- Advantage
- 58
View Lastest Price from VidofludiMus manufacturers
- Product
- Vidofludimus 717824-30-1
- Price
- US $0.00-0.00/Kg
- Min. Order
- 1Kg
- Purity
- 99.9%
- Supply Ability
- 200tons
- Release date
- 2024-04-07
- Product
- VidofludiMus 717824-30-1
- Price
- US $9.80/KG
- Min. Order
- 1g
- Purity
- ≥99%
- Supply Ability
- 100kg
- Release date
- 2020-01-12